Footnotes
  1. Centers for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Suppl 1987 Aug 14; 36 (1): 1S-15S.
  2. Kotler DP, et al. Magnitude of body-cell mass depletion and the timing of death from wasting in AIDS.Am J Clin Nutr 1989; 50: 444-7.
  3. Polsky B, et al. HIV-associated wasting in the HAART era: guidelines for assessment, diagnosis, and treatment. AIDS Patient Care STDs 2001: 15(8): 411-23.
  4. Wanke CA, et al. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31: 803-5.
  5. Erlandson KM, et al. Long-term impact of HIV wasting on physical function. AIDS 2016; 30: 445-54.
  6. Tang AM, et al. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31: 230-6.
  7. Wohlfeiler MB, et al. Association between incident HIV-associated wasting/low weight and all-cause mortality in the OPERA cohort.ID Week 2022, October 19–23, 2022.
  8. Siddiqui J, et al. The economic burden of HIV-associated wasting in the era of modern antiretroviral therapy. J Manag Care Spec Pharm 2022; 28(10): 1180-9.
  9. Jones JL, et al. Surveillance for AIDS-Defining Opportunistic Illnesses, 1992–1997. MMWR CDC Surveill Summ 1999; 48: 1-22.
  10. Smit E, et al. Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999. Am J Epidemiol 2002; 156: 211-8.
  11. Siddiqui J, et al. HIV-associated wasting prevalence in the era of modern antiretroviral theapy. AIDS 2022; 36: 127-35.
  12. Siddiqui J, et al. Prevalence and cost of HIV-associated weight loss in a managed care population. Curr Med Res Opin 2009; 25: 1307-17.
  13. Wohlfeiler MB, et al. Predictors of incident HIV-associated wasting and low weight in the OPERA Cohort, 2016-2021. ACTHIV, May 5–7, 2022.
  14. Gelato M, et al. Role of recombinant human growth hormone in HIV-associated wasting and cachexia: pathophysiology and rationale for treatment. Clin Ther 2007; 29(11): 2269-2288.
  15. Moyle GJ, et al. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35(4): 367-75.